DIACEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 131 GBX | -0.38% |
|
+1.16% | +50.57% |
| Jun. 12 | Transcript : Diaceutics PLC - Analyst/Investor Day | |
| Jun. 07 | YouGov brings Diaceutics Chair Deborah Davis onto board | AN |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 70.97 | 112.2 | 85.75 | 63.68 | 73.32 | 110.6 | - | - |
| Enterprise Value (EV) 1 | 59.25 | 87.1 | 66.08 | 43.84 | 56.65 | 97.77 | 96.58 | 92.4 |
| P/E ratio | 165 x | 393 x | - | 89.9 x | -42 x | -57.9 x | 122 x | 24.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5.3 x | 8.84 x | 6.15 x | 3.26 x | 3.09 x | 3.73 x | 2.92 x | 2.37 x |
| EV / Revenue | 4.42 x | 6.86 x | 4.74 x | 2.25 x | 2.39 x | 3.3 x | 2.55 x | 1.98 x |
| EV / EBITDA | 24.7 x | 162 x | 28.1 x | 12.2 x | 24 x | 34.1 x | 14.3 x | 8.34 x |
| EV / FCF | - | - | -13.1 x | 194 x | -16 x | -28.1 x | 70 x | 16.9 x |
| FCF Yield | - | - | -7.61% | 0.52% | -6.26% | -3.55% | 1.43% | 5.91% |
| Price to Book | - | - | - | 1.53 x | 1.8 x | 2.87 x | 2.72 x | 2.37 x |
| Nbr of stocks (in thousands) | 69,583 | 84,069 | 84,069 | 84,339 | 84,274 | 84,427 | - | - |
| Reference price 2 | 1.020 | 1.335 | 1.020 | 0.7550 | 0.8700 | 1.310 | 1.310 | 1.310 |
| Announcement Date | 3/16/20 | 3/15/21 | 3/22/22 | 4/17/23 | 5/21/24 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 13.4 | 12.7 | 13.94 | 19.5 | 23.7 | 29.62 | 37.86 | 46.76 |
| EBITDA 1 | 2.4 | 0.539 | 2.349 | 3.583 | 2.357 | 2.866 | 6.766 | 11.08 |
| EBIT 1 | 0.7404 | -0.658 | 0.55 | 0.574 | -3.018 | -2.493 | 1.424 | 5.919 |
| Operating Margin | 5.53% | -5.18% | 3.94% | 2.94% | -12.73% | -8.42% | 3.76% | 12.66% |
| Earnings before Tax (EBT) 1 | 0.4973 | -0.682 | - | 0.564 | -2.438 | -2.271 | 1.447 | 6.1 |
| Net income 1 | 0.3979 | 0.263 | 0.561 | 0.724 | -1.746 | -2.254 | 0.482 | 4.71 |
| Net margin | 2.97% | 2.07% | 4.02% | 3.71% | -7.37% | -7.61% | 1.27% | 10.07% |
| EPS 2 | 0.006200 | 0.003400 | - | 0.008400 | -0.0207 | -0.0226 | 0.0107 | 0.0541 |
| Free Cash Flow 1 | - | - | -5.031 | 0.226 | -3.544 | -3.475 | 1.379 | 5.463 |
| FCF margin | - | - | -36.08% | 1.16% | -14.95% | -11.73% | 3.64% | 11.68% |
| FCF Conversion (EBITDA) | - | - | - | 6.31% | - | - | 20.38% | 49.3% |
| FCF Conversion (Net income) | - | - | - | 31.22% | - | - | 286.12% | 115.99% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 3/15/21 | 3/22/22 | 4/17/23 | 5/21/24 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 11.98 | 9.924 | 13.78 | 11.72 | 17.67 |
| EBITDA 1 | - | - | 3.31 | -0.232 | 2.589 | -0.27 | 3.28 |
| EBIT 1 | - | - | 1.637 | -2.166 | -0.852 | -2.945 | 0.64 |
| Operating Margin | - | - | 13.67% | -21.83% | -6.19% | -25.13% | 3.62% |
| Earnings before Tax (EBT) 1 | - | - | 1.695 | -1.955 | -0.483 | -2.845 | 0.685 |
| Net income 1 | -0.335 | -0.767 | 1.491 | -1.485 | -0.261 | -2.745 | 0.64 |
| Net margin | - | - | 12.45% | -14.96% | -1.89% | -23.42% | 3.62% |
| EPS 2 | -0.004000 | -0.009100 | 0.0173 | -0.0176 | -0.003100 | -0.0323 | 0.007600 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 9/14/21 | 9/27/22 | 4/17/23 | 9/26/23 | 5/21/24 | - | - |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 11.7 | 25.1 | 19.7 | 19.8 | 16.7 | 12.8 | 14 | 18.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -5.03 | 0.23 | -3.54 | -3.47 | 1.38 | 5.46 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | 0.4900 | 0.4800 | 0.4600 | 0.4800 | 0.5500 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 2.93 | 6.29 | 5.6 | 4.87 | 4.86 | 5.85 | 5.85 | 5.1 |
| Capex / Sales | 21.84% | 49.57% | 40.17% | 24.97% | 20.49% | 19.75% | 15.45% | 10.91% |
| Announcement Date | 3/16/20 | 3/15/21 | 3/22/22 | 4/17/23 | 5/21/24 | - | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.31
GBP
Average target price
1.726
GBP
Spread / Average Target
+31.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +50.57% | 144M | |
| +23.01% | 4.72B | |
| -14.49% | 2.58B | |
| +53.42% | 2.4B | |
| +16.59% | 1.84B | |
| -14.12% | 1.51B | |
| -28.96% | 1.35B | |
| -28.72% | 1.26B | |
| -16.70% | 1.05B | |
| -34.79% | 715M |
- Stock Market
- Equities
- DXRX Stock
- Financials Diaceutics PLC
